Amgen Posts Strong Drug Sales, Beats Estimates
Amgen (AMGN) rose about 1% after beating earnings and revenue expectations. The biotech company posted $1.61 in EPS, 15 cents ahead of expectations. Revenue of $4.05 billion beat expectations for $3.93 billion. Its earnings and revenue guidance was in line with analysts’ expectations. Total product sales rose 8%, with sales of autoimmune drug Enbrel sales [...]

Amgen (AMGN) rose about 1% after beating earnings and revenue expectations.

The biotech company  posted $1.61 in EPS, 15 cents ahead of expectations. Revenue of $4.05 billion beat expectations for $3.93 billion. Its earnings and revenue guidance was in line with analysts’ expectations. Total product sales rose 8%, with sales of autoimmune drug Enbrel sales rising 7% and cancer therapy Neulasta/Neupogen jumping 9%.

“The pipeline is developing well and the business is in good shape to address the opportunities and challenges ahead,” said CEO Kevin Sharer in a statement.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here